Novartis AG
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Constant Currency Growth in Rest of World (% cc) by Quarter
Constant Currency Growth in Rest of World (% cc) (%)
Novartis Constant Currency Growth in Rest of World (% cc): -25.0% in Q3 2026, down 28.0 pts from a year earlier. That is the lowest of the 32 quarters on record here.
Where the Q3 2026 figure comes from
“|| Xolair 3 | Immunology | Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps, food allergy (FA) | 331 | – 25 | – 25 | 331 | – 25 | – 25”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Constant Currency Growth in Rest of World (% cc) (%), quarterly Q4 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-xolair-row-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.